Search

everythinglearnresearchcommunity

for

Search:↓

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Blocking a key energy pathway in human hair follicles can trigger stress responses that stop cell growth.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

Modifying steroidal inhibitors shows promise for developing new cancer treatments.

Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

Hedgehog pathway inhibitors could be effective in treating melanoma.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Isoalantolactone promotes hair growth by activating specific cell pathways.

ICP5249 helps hair grow by activating a specific cell pathway.

Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.

New steroid derivatives show promise as anticancer agents, even against resistant cells.

Lower doses of topotecan are safe for eyes, but higher doses may harm the retina.

Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.